PROBENECID | A084442 | WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Rising Pharma Holdings, Inc. FDA-2025-P-5431 · 9 docket documents Rising Pharma Holdings, Inc. filed this suitability petition pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act and 21 CFR § 314.93, requesting permission to file an Abbreviated New Drug Application for Probenecid Tablets USP in a 250 mg strength that differs from the Refere | Suitability | 2025-10-16 | Open | Rising Pharma Holdings, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.6601
per ea
Lowest NADAC/Unit
$0.6601
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00591534701PROBENECID 500 MG TABLET | $0.6601 | EA | Generic | — | 2026-06-17 |
| 00591534710PROBENECID 500 MG TABLET | $0.6601 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.